Education

Graduate School
Postgraduate Institute of Medical Education Research (1985)
Medical School
Postgraduate Institute-Med. Education & Research (1985)
Residency
Aurora St. Luke's Medical Center (1995), Pathology
Residency
New York Medical College (1997), Pathology
Residency
University Hospitals of Cleveland (1998), Pathology
Fellowship
University Hospitals of Cleveland (1999), Pathology

Research Interest

  • Biomarkers in breast cancer
  • Molecular testing in cytologic specimens

Publications

Featured Publications LegendFeatured Publications

Phase 1 study of ARQ 761, a ß-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.
Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA Br. J. Cancer 2018 Oct 119 8 928-936
Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY Breast Cancer Res. Treat. 2017 Jun
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA J Surg Oncol 2017 Mar
Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab.
Brown TJ, Sher DJ, Nedzi LA, Hughes RS, Beg MS, Mull J, Sarode VR, Khan SA Head Neck 2017 Feb
Effusive Constrictive Pericarditis in Autoimmune Polyglandular Syndrome Type II.
McNamara D, Yamamoto H, Sarode V, Zaha VG Am. J. Med. 2017 Feb
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA Cancer Cell 2016 Dec 30 6 940-952
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH Lung Cancer 2015 Oct
Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN, Raj G, Sarode V, Molberg KH, Vadlamudi RK, Peng Y Hum. Pathol. 2015 Aug
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF Mod. Pathol. 2015 Jul
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D Ann. Oncol. 2015 Jul 26 7 1280-91

Honors & Awards

  • The Vernie A. Stembridge Resident Teaching Award
    Presented annually in recognition of dedication and commitment to excellence in House StaffTeaching by UTSW Department of Pathology. (2006)

Professional Associations/Affiliations

  • American Society of Cytopathology (2014-2019)
  • USCAP (2008-2019)